Canada's National Advisory Committee on immunization: Adaptations and challenges during the COVID-19 pandemic.
(COVID-19 pandemic)
(NITAG)
(National Advisory Committee on Immunization)
(National Immunization Technical Advisory Group)
(Vaccine)
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
20 10 2023
20 10 2023
Historique:
received:
13
11
2022
revised:
04
06
2023
accepted:
18
08
2023
medline:
23
10
2023
pubmed:
2
9
2023
entrez:
1
9
2023
Statut:
ppublish
Résumé
The COVID-19 pandemic has challenged traditional vaccine guidance infrastructure and frameworks, and added urgency and complexity to the operation of National Immunization Technical Advisory Groups (NITAGs). Canada's National Advisory Committee on Immunization (NACI) provides immunization guidance to the Public Health Agency of Canada (PHAC) who publicly shares expert and evidence-informed guidance with Canadian provinces and territories. Throughout the pandemic, NACI and PHAC implemented many adaptations to meet urgent needs for pandemic vaccine guidance. In this paper, we describe: structural adaptations in response to the accelerated pace and amount of work required to issue recommendations that were timed around product authorizations and dynamic epidemiology; technical adaptations in response to rapidly evolving evidence of variable quality which required close monitoring, and which promoted reliance on basic vaccine principles due to incomplete direct evidence; the need to provide nimble advice (e.g., off-label recommendations, preferential recommendations); communications adaptations (e.g. identify sustainable spokespeople for the committee, receive stakeholder feedback, and ensure urgent nuanced advice was communicated to a diverse audience); and research adaptations focussing on solutions to constrained supply (e.g. prioritisation, extended intervals, and heterologous schedules). The early pandemic vaccine experience has created a roadmap of lessons and adaptations that should be leveraged in future pandemic vaccine programs, and has highlighted the essential role of NITAGs to complement regulatory structures during pandemics to ensure timely, impactful, and evidence-informed public health vaccine guidance.
Identifiants
pubmed: 37658002
pii: S0264-410X(23)00991-X
doi: 10.1016/j.vaccine.2023.08.048
pii:
doi:
Substances chimiques
Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6538-6547Informations de copyright
Crown Copyright © 2023. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Matthew Tunis, Shainoor Ismail, Marina Salvadori, Bryna Warshawsky, Kelsey Young, Christine Mauviel, and Erin Henry are employed by the Public Health Agency of Canada. Shelley Deeks and Robyn Harrison are the current Chair and Vice Chair of NACI, but not compensated for these roles. Caroline Quach was a previous Chair of NACI during the COVID-19 pandemic, but not compensated for this role. All authors contributed to the conception of the study, drafting the article, and approved the submitted version.